A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder

NCT ID: NCT00368030

Last Updated: 2012-02-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 545 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-01-31
• Study Completion Date: 2004-10-31

Brief Summary

The purpose of this study is to evaluate subjective sleep efficacy in subjects with insomnia related to major depressive disorder.

Detailed Description

This study is a double-blind, randomized, placebo-controlled, parallel group study. The study consists of two groups of subjects with major depression treated for ten weeks with a common antidepressant regimen, 20-40 mg of fluoxetine hydrochloride per day; and randomized to receive (in addition) either eszopiclone 3 mg or placebo for eight weeks. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Conditions

Insomnia; Depressive Disorder, Major

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

A

Eszopiclone 3 mg QD

Group Type: EXPERIMENTAL

Eszopiclone

Intervention Type: DRUG

Eszopiclone 3 mg QD

B

Placebo tablet

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo tablet

Interventions

Eszopiclone

Eszopiclone 3 mg QD

Intervention Type: DRUG

Placebo

Placebo tablet

Intervention Type: OTHER

Other Intervention Names

Lunesta, (S)-Zopliclone

Eligibility Criteria

Inclusion Criteria

• Subject must understand the purpose of the study and be willing to adhere to the study schedule and procedures described in this protocol.
• Subject must be 21 to 64 years of age (inclusive) on the day of signing consent.
• Subject must meet criteria for a primary and principal diagnosis of Major Depressive Disorder.
• Subject's current depressive episode is at least 2 weeks but not longer than 6 months in duration.
• Subject must meet criteria for insomnia related to MDD and the symptoms of insomnia must not pre-date the symptoms of MDD by more than 10 weeks.
• Subject must report a sleep onset time of > 30 minutes, and wake time after sleep onset of > 45 minutes, and < 6.5 hours of total sleep time at least three times a week over the previous month.
• Subject must take the Hamilton-D-17 scale and have a protocol pre-specified minimum score.
• Subject must have no known clinically significant abnormal laboratory, ECG, or physical examination findings at screening.
• Subject must meet one of the following conditions:
• Subject is not taking antidepressant medications at the time of study start.
• Subject is taking a sub-therapeutic dose of antidepressant or other disallowed psychotropic medication and with the approval of the investigator agrees to taper off of this medication, prior to completion of screening assessments at study start.

Exclusion Criteria

• Female subject is pregnant, lactating or within 6 months post partum.
• Subject has known sensitivity to any selective SSRI, zopiclone, or eszopiclone.
• Subject has history of major depressive disorder that was refractory to treatment with SSRIs.
• Subject has a current primary psychiatric diagnosis of any of the following disorders: dementia, delirium, schizophrenia, psychosis, other psychotic disorders, dysthymic disorder; bipolar disorders; cyclothymic disorder, other mood disorders, nocturnal panic disorder, primary anxiety disorders, primary panic disorders or any other psychiatric disorder that would compromise the investigator's ability to evaluate the safety and efficacy of the study medication.
• Note: Subjects with Sexual and Gender Identity Disorders or other non-psychotic disorders will be considered on a case-by-case basis. Subjects with MDD and a secondary diagnosis of generalized anxiety disorder, panic disorders other than nocturnal panic disorder or seasonal affective disorder will be allowed.
• Subject has any of the following Personality Disorders diagnoses: schizotypal, schizoid, borderline personality disorder; mental retardation or any other personality disorder that would compromise the investigator's ability to evaluate the safety and efficacy of the study medication.
• Subject has difficulties in sleep initiation or maintenance associated with known medical diagnosis [e.g. sleep apnea, restless leg syndrome (RLS), or periodic leg movement syndrome (PLMS)], or has any condition that has or may affect sleep [(e.g., chronic pain, benign prostatic hypertrophy (BPH)].
• Subject has any clinically significant unstable medical or neurologic abnormality, unstable chronic disease, or a history of a clinically significant abnormality of the cardiovascular, respiratory, hepatic, or renal systems.
• Subject has a disorder or history of a condition (e.g., malabsorption, gastrointestinal surgery) that may interfere with drug absorption, distribution, metabolism, or excretion.
• Subject has a history of malignancy within 5 years, or current malignancy, except for non-melanoma skin cancer.
• Subject has a history of drug or alcohol abuse or dependence in the past 6 months or positive urine drug and alcohol test at screening.
• Subject is participating in, has participated in, or plans to participate in any investigational drug study within 30 days prior to screening until the end of this study.
• Subject has history of circadian rhythm disorder, or travels across >3 time zones on a regular basis.
• Subject is known to be seropositive for Human Immunodeficiency Virus (HIV).
• Subject has used any drugs known or suspected to affect hepatic or renal clearance capacity within a period of 30 days prior to screening.
• Subject is unwilling to refrain from drinking alcoholic beverages during study participation.
• Subject is a rotating or third/night shift worker.
• Subject is a staff member or relative of a staff member.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sumitomo Pharma America, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Birmingham, Alabama, United States

Peoria, Arizona, United States

Tucson, Arizona, United States

Fayetteville, Arkansas, United States

Garden Grove, California, United States

Irvine, California, United States

Northridge, California, United States

Riverside, California, United States

San Diego, California, United States

Wheat Ridge, Colorado, United States

New Britian, Connecticut, United States

Jacksonville, Florida, United States

Miami, Florida, United States

Miami Beach, Florida, United States

North Miami, Florida, United States

St. Petersburg, Florida, United States

Atlanta, Georgia, United States

Augusta, Georgia, United States

Decatur, Georgia, United States

Smyrna, Georgia, United States

Boise, Idaho, United States

Overland Park, Kansas, United States

Rockville, Maryland, United States

Boston, Massachusetts, United States

Braintree, Massachusetts, United States

Brighton, Massachusetts, United States

Brockton, Massachusetts, United States

Cambridge, Massachusetts, United States

Watertown, Massachusetts, United States

Farmington Hills, Michigan, United States

St Louis, Missouri, United States

Omaha, Nebraska, United States

Clementon, New Jersey, United States

Morestown, New Jersey, United States

Lawerence, New York, United States

New York, New York, United States

The Bronx, New York, United States

Durham, North Carolina, United States

Winston-Salem, North Carolina, United States

Bismarck, North Dakota, United States

Beachwood, Ohio, United States

Cincinnati, Ohio, United States

Dayton, Ohio, United States

Oklahoma City, Oklahoma, United States

Eugene, Oregon, United States

Portland, Oregon, United States

Salem, Oregon, United States

Springfield, Oregon, United States

Conshohocken, Pennsylvania, United States

Emmaus, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

Scotland, Pennsylvania, United States

Anderson, South Carolina, United States

Madison, Tennessee, United States

Memphis, Tennessee, United States

Selmer, Tennessee, United States

Austin, Texas, United States

San Antonio, Texas, United States

Wichita Falls, Texas, United States

Salt Lake City, Utah, United States

Richmond, Virginia, United States

Lakewood, Washington, United States

Seatle, Washington, United States

Spokane, Washington, United States

Madison, Wisconsin, United States

Countries

United States

References

Snedecor SJ, Botteman MF, Schaefer K, Sarocco P, Barry N, Pickard AS. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder. J Ment Health Policy Econ. 2010 Mar;13(1):27-35.

Reference Type: RESULT

PMID: 20571180 (View on PubMed)

Fava M, Schaefer K, Huang H, Wilson A, Iosifescu DV, Mischoulon D, Wessel TC. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry. 2011 Apr;72(4):473-9. doi: 10.4088/JCP.09m05131gry. Epub 2010 Nov 2.

Reference Type: RESULT

PMID: 21208574 (View on PubMed)

Other Identifiers

190-052

Identifier Type: -

Identifier Source: org_study_id